Chronic Cough Market Share and Forecast by 2031

Historic Data: 2021-2022   |   Base Year: 2021   |   Forecast Period: 2023-2031

Chronic Cough Market Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Drug Class (Antihistamines, Corticosteroids, Decongestants, Combination Drug, Antibiotics, Acid Blockers, and Other Drug Class), Route of Administration (Oral, Injections, Inhalation, and Other Route of Administration), Distribution Channel (Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy), and Geography

  • Report Date : Nov 2025
  • Report Code : TIPRE00011584
  • Category : Life Sciences
  • Status : Data Released
  • Available Report Formats : pdf-format excel-format
  • No. of Pages : 150
Page Updated: Feb 2025

The chronic cough market size in 2021 stood at US$ 7.23 billion and is projected to reach US$ 13.60 billion by 2031 from US$ XX billion in 2023. The market is expected to register a CAGR of 8.2% in 2023–2031. Rising awareness regarding respiratory problems, along with advances in medical research and treatment choices, and continuous trend of drug development is likely to remain key chronic cough market trends.

 Chronic Cough Market Analysis

The global chronic cough market is primarily driven by the rising prevalence of chronic lung infections diseases, as persistent cough is a prevalent indication, and the development of new products to treat chronic cough. The market expansion is being driven by a considerable change towards prioritising respiratory health and wellness, as well as government and non-government initiatives.

 Chronic Cough Market Overview

A chronic cough continues for eight weeks or more. Infections, asthma, and gastric reflux sickness all contribute to its prevalence. Signs and symptoms of the chronic cough market include, a sensation of liquid running down the back of the throat (postnasal drip), and a headache, among others. Regular throat clearing, painful throat, hoarseness, shortness of breath, wheezing, sour odour in the mouth, or heartburn. There has been an increase in investment in healthcare infrastructure, diagnostic facilities, and patient education programmes to improve management and early detection of chronic cough.

Customize This Report To Suit Your Requirement

You will get customization on any report - free of charge - including parts of this report, or country-level analysis, Excel Data pack, as well as avail great offers and discounts for start-ups & universities

Chronic Cough Market: Strategic Insights

chronic-cough-market
  • Get Top Key Market Trends of this report.
    This FREE sample will include data analysis, ranging from market trends to estimates and forecasts.

Chronic Cough Market Drivers and Opportunities

Growing Adoption of Chronic Cough to Favor Market Growth

The conditions such as infection, lung diseases, and bronchitis are also likely to lead to chronic cough. The condition such as asthma is rising globally; it is commonly seen among children and adults. According to a study titled “Prevalence of chronic cough, its risk factors and population attributable risk in the Burden of Obstructive Lung Disease (BOLD) study: a multinational cross-sectional study” published in February 2024, the prevalence for chronic cough ranged from 2% to 18%. Smoking, asthma, chronic obstructive pulmonary disease (COPD), obesity, upper airway cough syndrome (UACS), and gastro-oesophageal reflux disease (GORD) are some of the factors that have most commonly been associated with chronic cough.

Rising Aging Population is Expected to Drive Demand for Chronic Cough Treatment Market

Older people are more prone to have a chronic cough, and the growing age is the prime factors of decreased immunity. The degeneration of the organs and healthy tissues due to age factor invites several health conditions. Chronic cough is one of the commonly seen health conditions among older people. The respiratory system starts degenerating as the age progresses. Therefore, the chances of suffering from respiratory infections, such as pneumonia and the flu increases in older people.

The aging population is growing across the world, as developed and developing countries are witnessing a decreased death rate. The developments in the healthcare industry have enhanced public health resulting in increased life expectancy. According to WHO, by 2050, the world’s population of people aged 60 years and above will reach to 2.1 billion. The number of persons aged 80 years or older is expected to triple between 2020 and 2050 to reach 426 million. Therefore, it expected that the growing geriatric population is likely to demand more chronic cough treatment during the forecast period.

Chronic Cough Market Report Segmentation Analysis

Key segments that contributed to the derivation of the chronic cough market analysis are drug class, route of administration, and distribution channel.

  • Based on drug class, the chronic cough market is segmented into antihistamines, corticosteroids, decongestants, combination drug, antibiotics, acid blockers, and other drug class. The combination drug segment held a larger market share in 2023.
  • By route of administration, the market is divided into oral, injections, inhalation, other route of administration. The oral segment held the larger share of the market in 2023.
  • In terms of distribution channel, the market is segmented into hospital pharmacy, online pharmacy, and retail pharmacy. The hospital pharmacy segment dominated the market in 2023.

 

Chronic Cough Market Share Analysis by Geography

The geographic scope of the chronic cough market report is mainly divided into five regions: North America, Asia Pacific, Europe, Middle East & Africa, and South & Central America.

North America has dominated the chronic cough market. The rising demand for over the counter (OTC) products is a main factor projected to drive growth revenue of the region in the review period. In addition, an increasing number of chronic cough cases, rapidly growing elderly population, rising vehicle pollution, and growing awareness about advanced medicines are among some of the other factors that drive the demand for cough remedies products.  

Chronic Cough Market Regional Insights

The regional trends and factors influencing the Chronic Cough Market throughout the forecast period have been thoroughly explained by the analysts at The Insight Partners. This section also discusses Chronic Cough Market segments and geography across North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America.

Chronic Cough Market Report Scope

Report Attribute Details
Market size in 2021 US$ 7.23 Billion
Market Size by 2031 US$ 13.60 Billion
Global CAGR (2023 - 2031) 8.2%
Historical Data 2021-2022
Forecast period 2023-2031
Segments Covered By Drug Class
  • Antihistamines
  • Corticosteroids
  • Decongestants
  • Combination Drug
  • Antibiotics
  • Acid Blockers
  • Other Drug Class
By Route of Administration
  • Oral
  • Injections
  • Inhalation
  • Other Route of Administration
By Distribution Channel
  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy
Regions and Countries Covered North America
  • US
  • Canada
  • Mexico
Europe
  • UK
  • Germany
  • France
  • Russia
  • Italy
  • Rest of Europe
Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
South and Central America
  • Brazil
  • Argentina
  • Rest of South and Central America
Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa
Market leaders and key company profiles
  • Novartis AG
  • Teva Pharmaceutical Industries Ltd
  • Glaxo SmithKline plc
  • Bayer AG
  • Mylan N.V.
  • Amneal Pharmaceuticals Inc
  • Cipla Inc
  • Reckitt Benckiser Group plc
  • Sun Pharmaceutical Industries Ltd
  • Aurobindo Pharma Ltd

Chronic Cough Market Players Density: Understanding Its Impact on Business Dynamics

The Chronic Cough Market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.


chronic-cough-market-cagr

  • Get the Chronic Cough Market top key players overview

Chronic Cough Market News and Recent Developments

The chronic cough market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. The following is a list of developments in the market for chronic cough:

  • Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio (oral nalbuphine ER) for patients with chronic cough in idiopathic pulmonary fibrosis (IPF), refractory chronic cough (RCC), and prurigo nodularis, announced the initiation of its Phase 2b CORAL clinical trial evaluating three doses of Haduvio against placebo in approximately 160 IPF patients with chronic cough. (Source: The Trevi Therapeutics, Press Release, 2023)
  • Algernon Pharmaceuticals Inc., a Canadian clinical stage pharmaceutical development company, is pleased to announce that it has closed on its agreement with Seyltx Inc., a privately owned U.S. based drug development company, for the acquisition of Algernon’s NP-120 (“Ifenprodil”) research program. (Source: Algernon Pharmaceuticals Inc., Press Release, 2024)

 Chronic Cough Market Report Coverage and Deliverables

The “Chronic CoughMarket Size and Forecast (2021–2031)” report provides a detailed analysis of the market covering below areas:

  • Market size and forecast at global, regional, and country levels for all the key market segments covered under the scope
  • Market dynamics such as drivers, restraints, and key opportunities
  • Key future trends
  • Detailed PEST/Porter’s Five Forces and SWOT analysis
  • Global and regional market analysis covering key market trends, major players, regulations, and recent market developments
  • Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments
  • Detailed company profiles
Mrinal Kerhalkar
Manager,
Market Research & Consulting

Mrinal is a seasoned research analyst with over 8 years of experience in Life Sciences Market Intelligence and Consulting. With a strategic mindset and unwavering commitment to excellence, she has built deep expertise in pharmaceutical forecasting, market opportunity assessment, and developing industry benchmarks. Her work is anchored in delivering actionable insights that empower clients to make informed strategic decisions.

Mrinal’s core strength lies in translating complex quantitative datasets into meaningful business intelligence. Her analytical acumen is instrumental in shaping go-to-market (GTM) strategies and uncovering growth opportunities across the pharmaceutical and medical device sectors. As a trusted consultant, she consistently focuses on streamlining workflow processes and establishing best practices, thereby driving innovation and operational efficiency for her clients.

  • Historical Analysis (2 Years), Base Year, Forecast (7 Years) with CAGR
  • PEST and SWOT Analysis
  • Market Size Value / Volume - Global, Regional, Country
  • Industry and Competitive Landscape
  • Excel Dataset

Testimonials

Reason to Buy

  • Informed Decision-Making
  • Understanding Market Dynamics
  • Competitive Analysis
  • Identifying Emerging Markets
  • Customer Insights
  • Market Forecasts
  • Risk Mitigation
  • Boosting Operational Efficiency
  • Strategic Planning
  • Investment Justification
  • Tracking Industry Innovations
  • Aligning with Regulatory Trends
Our Clients
Sales Assistance
US: +1-646-491-9876
UK: +44-20-8125-4005
Email: sales@theinsightpartners.com
Chat with us
DUNS Logo
87-673-9708
ISO Certified Logo
ISO 9001:2015
ISO Certified Logo